Recent Updates
Recently added Catalysts
FULC

Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference

Key Takeaway: CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fires
Price reaction · baseline $9.5 (2022-05-04 close) · hit after-hours · 2 other FULC headline(s) in the window, move may be shared
day 0 close
-7.3%
day 1
-9.2%
day 3 · peak
-20.5%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
15.6%
average across 6 past catalysts
Cash runway
~59 mo
Minimal dilution risk
Lead asset
Pociredir
Phase 2 · Sickle Cell Disease

Full Press Release Details

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference, on Thursday, May 12, 2022 at 11:20 a.m. PT (2:20 p.m. ET).
A live audio webcast will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. An archived replay will be available on the Company’s website for 30 days.
About Fulcrum Therapeutics
Stern Investor Relations, Inc.
Last updated: May 5, 2022